Advances in mass spectrometry-based clinical biomarker discovery

Christopher A. Crutchfield, Stefani N. Thomas, Lori J Sokoll, Daniel Wan-Yui Chan

Research output: Contribution to journalArticle

Abstract

The greatest unmet needs in biomarker discovery are those discoveries that lead to the development of clinical diagnostic tests. These clinical diagnostic tests can provide early intervention when a patient would present otherwise healthy (e.g., cancer or cardiovascular disease) and aid clinical decision making with improved clinical outcomes. The past two decades have seen significant technological improvements in the analytical capabilities of mass spectrometers. Mass spectrometers are unique in that they can directly analyze any biological molecule susceptible to ionization. The biological studies of human metabolites and proteins using contemporary mass spectrometry technology (metabolomics and proteomics, respectively) has been ongoing for over a decade. Some of these studies have resulted in exciting insights into human biology. However, relatively few biomarkers have been translated into clinical tests. This review will discuss some key technological developments that have occurred over this time with an emphasis on technologies that will create new avenues for biomarker discovery.

Original languageEnglish (US)
Article number13
JournalClinical Proteomics
Volume13
Issue number1
DOIs
StatePublished - Jan 7 2016

Fingerprint

Biomarkers
Mass spectrometry
Mass Spectrometry
Mass spectrometers
Routine Diagnostic Tests
Technology
Metabolomics
Metabolites
Proteomics
Ionization
Cardiovascular Diseases
Decision making
Molecules
Neoplasms
Proteins

Keywords

  • Biomarker
  • Clinical performance
  • Mass spectrometry
  • Proteomics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Clinical Biochemistry

Cite this

Advances in mass spectrometry-based clinical biomarker discovery. / Crutchfield, Christopher A.; Thomas, Stefani N.; Sokoll, Lori J; Chan, Daniel Wan-Yui.

In: Clinical Proteomics, Vol. 13, No. 1, 13, 07.01.2016.

Research output: Contribution to journalArticle

Crutchfield, Christopher A. ; Thomas, Stefani N. ; Sokoll, Lori J ; Chan, Daniel Wan-Yui. / Advances in mass spectrometry-based clinical biomarker discovery. In: Clinical Proteomics. 2016 ; Vol. 13, No. 1.
@article{7e9bf787fdc8407aa2697450e27fc7e5,
title = "Advances in mass spectrometry-based clinical biomarker discovery",
abstract = "The greatest unmet needs in biomarker discovery are those discoveries that lead to the development of clinical diagnostic tests. These clinical diagnostic tests can provide early intervention when a patient would present otherwise healthy (e.g., cancer or cardiovascular disease) and aid clinical decision making with improved clinical outcomes. The past two decades have seen significant technological improvements in the analytical capabilities of mass spectrometers. Mass spectrometers are unique in that they can directly analyze any biological molecule susceptible to ionization. The biological studies of human metabolites and proteins using contemporary mass spectrometry technology (metabolomics and proteomics, respectively) has been ongoing for over a decade. Some of these studies have resulted in exciting insights into human biology. However, relatively few biomarkers have been translated into clinical tests. This review will discuss some key technological developments that have occurred over this time with an emphasis on technologies that will create new avenues for biomarker discovery.",
keywords = "Biomarker, Clinical performance, Mass spectrometry, Proteomics",
author = "Crutchfield, {Christopher A.} and Thomas, {Stefani N.} and Sokoll, {Lori J} and Chan, {Daniel Wan-Yui}",
year = "2016",
month = "1",
day = "7",
doi = "10.1186/s12014-015-9102-9",
language = "English (US)",
volume = "13",
journal = "Clinical Proteomics",
issn = "1542-6416",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Advances in mass spectrometry-based clinical biomarker discovery

AU - Crutchfield, Christopher A.

AU - Thomas, Stefani N.

AU - Sokoll, Lori J

AU - Chan, Daniel Wan-Yui

PY - 2016/1/7

Y1 - 2016/1/7

N2 - The greatest unmet needs in biomarker discovery are those discoveries that lead to the development of clinical diagnostic tests. These clinical diagnostic tests can provide early intervention when a patient would present otherwise healthy (e.g., cancer or cardiovascular disease) and aid clinical decision making with improved clinical outcomes. The past two decades have seen significant technological improvements in the analytical capabilities of mass spectrometers. Mass spectrometers are unique in that they can directly analyze any biological molecule susceptible to ionization. The biological studies of human metabolites and proteins using contemporary mass spectrometry technology (metabolomics and proteomics, respectively) has been ongoing for over a decade. Some of these studies have resulted in exciting insights into human biology. However, relatively few biomarkers have been translated into clinical tests. This review will discuss some key technological developments that have occurred over this time with an emphasis on technologies that will create new avenues for biomarker discovery.

AB - The greatest unmet needs in biomarker discovery are those discoveries that lead to the development of clinical diagnostic tests. These clinical diagnostic tests can provide early intervention when a patient would present otherwise healthy (e.g., cancer or cardiovascular disease) and aid clinical decision making with improved clinical outcomes. The past two decades have seen significant technological improvements in the analytical capabilities of mass spectrometers. Mass spectrometers are unique in that they can directly analyze any biological molecule susceptible to ionization. The biological studies of human metabolites and proteins using contemporary mass spectrometry technology (metabolomics and proteomics, respectively) has been ongoing for over a decade. Some of these studies have resulted in exciting insights into human biology. However, relatively few biomarkers have been translated into clinical tests. This review will discuss some key technological developments that have occurred over this time with an emphasis on technologies that will create new avenues for biomarker discovery.

KW - Biomarker

KW - Clinical performance

KW - Mass spectrometry

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=84953285021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953285021&partnerID=8YFLogxK

U2 - 10.1186/s12014-015-9102-9

DO - 10.1186/s12014-015-9102-9

M3 - Article

C2 - 26751220

AN - SCOPUS:84953285021

VL - 13

JO - Clinical Proteomics

JF - Clinical Proteomics

SN - 1542-6416

IS - 1

M1 - 13

ER -